183,304 Shares in Hims & Hers Health, Inc. $HIMS Acquired by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 183,304 shares of the company’s stock, valued at approximately $10,397,000. Emerald Mutual Fund Advisers Trust owned about 0.08% of Hims & Hers Health as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $26,000. Quent Capital LLC purchased a new position in Hims & Hers Health during the third quarter worth about $28,000. Quaker Wealth Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at about $29,000. Bessemer Group Inc. boosted its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the 1st quarter valued at approximately $30,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $308,767.81. Following the transaction, the insider owned 2,126 shares of the company’s stock, valued at $78,045.46. This trade represents a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 134,611 shares of company stock worth $4,895,914. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $30.51 on Friday. The firm has a 50 day moving average of $35.10 and a two-hundred day moving average of $45.21. The stock has a market capitalization of $6.95 billion, a PE ratio of 56.50, a P/E/G ratio of 4.90 and a beta of 2.37. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a 52 week low of $23.97 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same quarter in the previous year, the business posted $0.32 earnings per share. The firm’s revenue was up 49.2% on a year-over-year basis. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has approved a stock repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Barclays initiated coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target on the stock. UBS Group set a $32.00 target price on Hims & Hers Health in a research report on Tuesday, November 4th. KeyCorp assumed coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating for the company. Leerink Partners raised Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus price target of $44.54.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.